PDCD1 and neoplasm: In this retrospective study, molecular and mutational biomarkers such as PD-L1 and TMB and the mutational profile in tumor and blood were analyzed in patients with cSCC undergoing treatment with PD-1 inhibitors in order to compare with treatment response, describe correlations, and possibly identify potential predictors of response.